DNA Topoisomerase II Inhibition Potentiates Osimertinib's Therapeutic Efficacy in EGFR-mutant Non-small Cell Lung Cancer Models

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2024 Mar 7

PMID 38451729

Authors

Zhen Chen

Karin A Vallega

Dongsheng Wang

Zihan Quan

Songqing Fan

Qiming Wang

Ticiana Leal

Suresh S Ramalingam

Shi-Yong Sun

Affiliations

Soon will be listed here.

Abstract

Development of effective strategies to manage the inevitable acquired resistance to osimertinib, a third-generation EGFR inhibitor for the treatment of EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), is urgently needed. This study reports that DNA topoisomerase II (Topo II) inhibitors, doxorubicin and etoposide, synergistically decreased cell survival, with enhanced induction of DNA damage and apoptosis in osimertinib-resistant cells; suppressed the growth of osimertinib-resistant tumors; and delayed the emergence of osimertinib-acquired resistance. Mechanistically, osimertinib decreased Topo IIα levels in EGFRm NSCLC cells by facilitating FBXW7-mediated proteasomal degradation, resulting in induction of DNA damage; these effects were lost in osimertinib-resistant cell lines that possess elevated levels of Topo IIα. Increased Topo IIα levels were also detected in the majority of tissue samples from patients with NSCLC after relapse from EGFR tyrosine kinase inhibitor treatment. Enforced expression of an ectopic TOP2A gene in sensitive EGFRm NSCLC cells conferred resistance to osimertinib, whereas knockdown of TOP2A in osimertinib-resistant cell lines restored their susceptibility to osimertinib-induced DNA damage and apoptosis. Together, these results reveal an essential role of Topo IIα inhibition in mediating the therapeutic efficacy of osimertinib against EGFRm NSCLC, providing scientific rationale for targeting Topo II to manage acquired resistance to osimertinib.

Citing Articles

Roles and therapeutic opportunities of ω-3 long-chain polyunsaturated fatty acids in lung cancer.

Luo J, Peng S, Jiang Z, Wang Q, Zhang M, Zeng Y iScience. 2025; 28(1):111601.

PMID: 39834867 PMC: 11742864. DOI: 10.1016/j.isci.2024.111601.

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.

Chen Z, Vallega K, Wang D, Quan Z, Fan S, Wang Q J Exp Med. 2024; 221(11).

PMID: 39297884 PMC: 11413468. DOI: 10.1084/jem.20240435.

Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.

Chen Z, Vallega K, Boda V, Quan Z, Wang D, Fan S Adv Sci (Weinh). 2024; 11(35):e2310126.

PMID: 39044361 PMC: 11425210. DOI: 10.1002/advs.202310126.

References

Chen Z, Yu D, Owonikoko T, Ramalingam S, Sun S . Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene. 2021; 40(49):6653-6665. PMC: 8671366. DOI: 10.1038/s41388-021-02057-0. View

Sharma A, Singh K, Almasan A . Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012; 920:613-26. DOI: 10.1007/978-1-61779-998-3_40. View

Hayashi R, Inomata M . Small cell lung cancer; recent advances of its biology and therapeutic perspective. Respir Investig. 2021; 60(2):197-204. DOI: 10.1016/j.resinv.2021.10.008. View

Bjornsti M, Kaufmann S . Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. F1000Res. 2019; 8. PMC: 6774054. DOI: 10.12688/f1000research.20201.1. View

Ivashkevich A, Redon C, Nakamura A, Martin R, Martin O . Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett. 2011; 327(1-2):123-33. PMC: 3329565. DOI: 10.1016/j.canlet.2011.12.025. View

Gomatou G, Syrigos N, Kotteas E . Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. Cancers (Basel). 2023; 15(3). PMC: 9913144. DOI: 10.3390/cancers15030841. View

Fillmore C, Xu C, Desai P, Berry J, Rowbotham S, Lin Y . EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015; 520(7546):239-42. PMC: 4393352. DOI: 10.1038/nature14122. View

Oronsky B, Abrouk N, Caroen S, Lybeck M, Guo X, Wang X . A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC). J Cancer. 2022; 13(9):2945-2953. PMC: 9330463. DOI: 10.7150/jca.75622. View

Zalaquett Z, Hachem M, Kassis Y, Hachem S, Eid R, Kourie H . Acquired resistance mechanisms to osimertinib: The constant battle. Cancer Treat Rev. 2023; 116:102557. DOI: 10.1016/j.ctrv.2023.102557. View

10.

Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S . Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC. N Engl J Med. 2023; 389(21):1935-1948. DOI: 10.1056/NEJMoa2306434. View

11.

Pommier Y, Nussenzweig A, Takeda S, Austin C . Human topoisomerases and their roles in genome stability and organization. Nat Rev Mol Cell Biol. 2022; 23(6):407-427. PMC: 8883456. DOI: 10.1038/s41580-022-00452-3. View

12.

Lee A, Yuan Y, Eccles L, Chitkara A, Dalen J, Varol N . Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies. Cancer Treat Res Commun. 2022; 33:100648. DOI: 10.1016/j.ctarc.2022.100648. View

13.

Sun S, Yue P, Dawson M, Shroot B, Michel S, Lamph W . Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 1997; 57(21):4931-9. View

14.

Shi P, Oh Y, Deng L, Zhang G, Qian G, Zhang S . Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clin Cancer Res. 2017; 23(21):6567-6579. PMC: 5668147. DOI: 10.1158/1078-0432.CCR-17-1574. View

15.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

16.

Zhu L, Chen Z, Zang H, Fan S, Gu J, Zhang G . Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer Res. 2021; 81(18):4822-4834. PMC: 8448971. DOI: 10.1158/0008-5472.CAN-21-0556. View

17.

Gu J, Yao W, Shi P, Zhang G, Owonikoko T, Ramalingam S . MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Cancer. 2020; 126(16):3788-3799. PMC: 7381372. DOI: 10.1002/cncr.32996. View

18.

Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu Y, Liu L . Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639-42. DOI: 10.1038/nm.2919. View

19.

Cabanos H, Hata A . Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers (Basel). 2021; 13(11). PMC: 8198243. DOI: 10.3390/cancers13112666. View

20.

Chen M, Chen C, Chuang H, Kulp S, Teng C, Chen C . Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells. Hepatology. 2011; 53(1):148-59. PMC: 3058595. DOI: 10.1002/hep.23964. View